OXURION overview

Leuven, BELGIUM – March 27, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received transparency notifications as follows: Oxurion received a transparency notification on March 27, 2025, from Atlas Special Opportunities II, LLC indicating that as of March 20, 2025, it held 52,489 shares of the then outstanding 3,638,344 shares, and therefore crossed...

Leuven, BELGIUM – March 27, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received an amended transparency notification as follows: Oxurion received a transparency notification on March 27, 2025, from Atlas Special Opportunities II, LLC indicating that as of March 17, 2025, it held 134,344 shares of the then outstanding 3,638,344 shares, and therefore...

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment [1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM – 24 March, 2025 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2,...

Louvain, BELGIUM – March 18, 2025 – 6:30 PM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the signing of a letter of intent (LOI) for the planned acquisition of a majority stake in a Contract Research Organization (CRO) specialized in clinical data management and biometric analysis. This planned acquisition aligns with Oxurion's strategy to expand its expertise by developing an integrated offering for pharmaceutical and biotech...

Leuven, BELGIUM – March 18, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received transparency notifications as follows: Oxurion received a transparency notification on March 18, 2025, from Atlas Special Opportunities, LLC indicating that as of February 17, 2025, it held 485,109 shares of the then outstanding 3,638,344 shares, and therefore crossed...

LEUVEN, BELGIUM – March 4, 2025 – 07:00PM – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the signing of a third amendment to its convertible bond subscription agreement with Atlas Special Opportunities, LLC. As part of this amendment, the agreement has been assigned to Atlas Special Opportunities II, LLC. This amendment extends the issuance period under adjusted conditions and clarifies the maturity terms of all outstanding and future...

LEUVEN, BELGIUM - February 14, 2024 - 7:00PM , Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces a change in its Board of Directors with the departure of Ms. Anat Loewenstein and Ms. Nathalie Laarakker, effective as of January 13, 2025, and the integration of Nelly Souleymane as an independent director, coopted by the Board of Directors. These changes are part of Oxurion's strategy to strengthen the diversity and complementarity of expertise...

Leuven, BELGIUM – January 20, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on January 16, 2025, from Atlas Special Opportunities, LLC indicating that as of January 13, 2025, it held 812,202 shares of the then outstanding 3,638,344 shares, and therefore...